Tower Research Capital (TRC)’s Jyong Biotech MENS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.16K Buy
3,491
+2,421
+226% +$5.29K ﹤0.01% 4490
2026
Q2
$2.22K Sell
1,070
-10,633
-91% -$22.6K ﹤0.01% 4703
2026
Q1
$25.2K Buy
11,703
+6,918
+145% +$16.9K ﹤0.01% 3318
2025
Q4
$18.9K Buy
4,785
+4,759
+18,304% +$168K ﹤0.01% 3136
2025
Q3
$1.02K Buy
+26
New +$936 ﹤0.01% 4892

Other funds holding MENS

Tower Research Capital (TRC)'s MENS Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Jyong Biotech (MENS) stake by 226% in Q3 2026, buying an estimated $5.29K and bringing the position to 3,491 shares worth $7.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4490.

Tower Research Capital (TRC) first reported a position in MENS in Q3 2025 and has held it in 5 quarters since. The position peaked at $25.2K in Q1 2026. 17 funds tracked by Wall St. Rank hold MENS as of Q3 2026.

  • Tower Research Capital (TRC) held 3,491 shares of Jyong Biotech worth $7.16K as of Q3 2026.
  • Tower Research Capital (TRC) bought 2,421 Jyong Biotech shares in Q3 2026, an estimated $5.29K.
  • Jyong Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4490 holding.
  • Tower Research Capital (TRC) first reported a position in Jyong Biotech in Q3 2025 and has held it in 5 quarters since.
  • Tower Research Capital (TRC)'s Jyong Biotech position peaked at $25.2K in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.